Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Molecular Targeting of the Claudins Pathway.

Version 1 : Received: 20 January 2024 / Approved: 22 January 2024 / Online: 22 January 2024 (10:02:04 CET)

How to cite: Hana, C.; Thaw Dar, N.N.; Galo Venegas, M.; Vulfovich, M. Molecular Targeting of the Claudins Pathway.. Preprints 2024, 2024011546. https://doi.org/10.20944/preprints202401.1546.v1 Hana, C.; Thaw Dar, N.N.; Galo Venegas, M.; Vulfovich, M. Molecular Targeting of the Claudins Pathway.. Preprints 2024, 2024011546. https://doi.org/10.20944/preprints202401.1546.v1

Abstract

Claudins are a family of 27 proteins that have an important role in the formation of tight junc-tions. They also have an important function in ions exchange, cell mobility, and in in the epitheli-al-to-mesenchymal transition, the latter being very important in cancer invasion and metastasis. Therapeutic targeting of claudins has been investigated to improve cancer outcomes. Recent evi-dence shows improved outcomes when combining monoclonal antibodies against Claudin 18.2 with chemotherapy for patients with gastroesophageal junction cancer. Currently Chimeric anti-gen receptor T-cells targeting Claudin 18 are under investigation.

Keywords

Claudin; monoclonal antibodies; adenocarcinoma; targeted therapy; CAR-T cell therapy

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.